Introducing valeda light therapy

A non-invasive treatment supporting Dry AMD. Learn more or schedule now.

Valeda® Light Delivery System

Introducing Valeda®: The First Treatment to Improve Vision in Dry AMD

The Valeda Light Delivery System is the first and only FDA‑authorized treatment designed to improve visual acuity in patients with early‑ to intermediate‑stage dry AMD.

Authorized by the FDA in November 2024, Valeda uses photobiomodulation (PBM) — specific wavelengths of low‑level light — to stimulate cellular energy production and support healthier retinal cells.

what is Valeda?

How Valeda Helps:

Valeda delivers three wavelengths of light. These wavelengths boost mitochondrial activity, increase cellular energy, reduce oxidative stress, and support healthier retinal function.

Clinical studies, including the LIGHTSITE III trial, show that Valeda treatment can improve vision by approximately one line on the ETDRS eye chart over two years compared to untreated eyes.

Who Is a Candidate for Valeda?

Valeda is intended for patients with:

  • Best‑corrected visual acuity between 20/32 and 20/70
  • Dry AMD with:
    • At least 3 medium drusen, or
    • Large drusen, or
    • Non‑central geographic atrophy
  • No neovascular (wet) AMD
  • No center‑involving geographic atrophy

Your doctor will determine whether you meet the clinical criteria for treatment.

Want to Learn More?

For details about treatment frequency, insurance considerations, safety information, and what happens during each visit, visit our Valeda FAQ & What to Expect page.

🌈 See Your Future More Clearly

Valeda represents a breakthrough in the treatment of dry AMD — offering hope, improved vision, and healthier retinal function for patients who previously had no treatment options.

If you or a loved one has dry AMD, talk to your eye doctor to see whether Valeda is right for you.

Specialty Eyecarè Centre

Accessibility Toolbar